Ivermectin is the new hydroxychloroquine

During the first years of the COVID-19 pandemic, many of us secretly hoped there was a simple,
cheap pill hiding in plain sight that could shut the whole thing down. Instead of a tidy Hollywood
ending, we got hydroxychloroquine, then ivermectin two perfectly useful medications in their
original roles that were promoted as miracle COVID cures long before solid evidence showed
otherwise.

The phrase “ivermectin is the new hydroxychloroquine” comes from science communicators and
skeptical physicians who watched the same story unfold twice: a drug with a plausible-sounding
theory, a few low-quality studies, and a viral wave of online enthusiasm, followed by larger,
better trials that failed to show meaningful benefit. In other words, science moved slowly and
carefully; social media sprinted.

This article breaks down how we got here, what the evidence actually says about ivermectin and
hydroxychloroquine for COVID-19, why these drugs became political symbols, and what this saga
can teach us about science-based medicine (and how not to fall for the next “miracle cure”
headline).

How We Got Here: The Search for a COVID Miracle Pill

In early 2020 the world was desperate. Hospitals were overwhelmed, vaccines didn’t exist yet,
and doctors were trying repurposed medications in real time. That’s normal in a crisis:
researchers scan shelves for existing drugs that might plausibly work against a new disease.

Hydroxychloroquine, originally developed for malaria and widely used for lupus and rheumatoid
arthritis, quickly became a pandemic celebrity. A small French study with major flaws suggested
it might reduce viral load in COVID-19 patients. It was tiny, uncontrolled, and later heavily
criticized but the hopeful headline was already out in the wild, boosted on TV, social media,
and even from the White House.

Before long, hydroxychloroquine got an Emergency Use Authorization (EUA) from the U.S. Food and
Drug Administration (FDA) to treat certain hospitalized COVID-19 patients. As better-designed
randomized controlled trials came in, the story changed: the drug didn’t improve survival,
didn’t shorten hospital stays, and did raise concerns about heart rhythm problems in some
people. The FDA revoked the EUA in June 2020, concluding that hydroxychloroquine was unlikely
to be effective for COVID-19 and that its potential risks outweighed its potential benefits
for this use.

That should have been the end of the “magic pill” chapter. Instead, we got a sequel.

Hydroxychloroquine: Rise and Fall of an Early Pandemic Star

To understand why ivermectin became “the new hydroxychloroquine,” it helps to see what
hydroxychloroquine’s arc looked like:

What hydroxychloroquine is actually for

Hydroxychloroquine is a legitimate, valuable medication for malaria prevention and for certain
autoimmune diseases like lupus and rheumatoid arthritis. Millions of people rely on it for
those conditions. That has never been in question.

The hype machine

Early lab studies suggested hydroxychloroquine might interfere with the virus’s ability to
enter cells. A few small, uncontrolled clinical studies hinted at benefit. Those hints became
headlines, and headlines morphed into certainty in some corners of media and politics. Demand
exploded, sometimes leaving patients with lupus scrambling to refill necessary prescriptions.

What the trials showed

As larger randomized controlled trials were completed, the results were remarkably consistent:
hydroxychloroquine did not reduce mortality, did not keep people off ventilators, and did not
meaningfully improve outcomes for COVID-19. Some studies signaled an increased risk of heart
rhythm problems when the drug was used at higher doses or combined with other medications.

In short: a good drug for some diseases, a bad bet for COVID-19.

Enter Ivermectin: From Parasite Killer to Pandemic Celebrity

While hydroxychloroquine was losing its shine, a new candidate stepped into the spotlight:
ivermectin. If hydroxychloroquine was the first season of the “miracle cure” show, ivermectin
was season two with a bigger budget and even wilder plot twists.

Ivermectin’s real job description

Ivermectin is an antiparasitic drug that has transformed the treatment of diseases like river
blindness (onchocerciasis), certain intestinal worm infections, and scabies. It won its
developers a share of the Nobel Prize for its impact on global health. It is approved in
humans for specific parasitic infections and, separately, formulated at different doses for
large animals like horses and cattle.

The petri dish problem

In 2020, lab studies showed that ivermectin could inhibit SARS-CoV-2 (the virus that causes
COVID-19) in cell culture at very high concentrations. That’s not inherently bad news many
antivirals start as promising lab findings but the doses needed to replicate those effects in
humans were much higher than what’s safe or approved. The leap from “kills virus in a dish” to
“safely treats humans at realistic doses” was huge, and early on there was no bridge spanning
that gap.

Small studies, big claims

Soon, small and often poorly designed clinical studies began circulating online, some as
preprints that had not undergone peer review. A few reported dramatic benefits: large
reductions in mortality, faster recovery, fewer hospitalizations. These eye-popping results
were heavily promoted by advocacy groups, social media influencers, and some physicians. But as
researchers began scrutinizing the data, serious problems emerged from sloppy methodology all
the way to suspected fraud in some trials.

Just like hydroxychloroquine, ivermectin’s public image sprinted far ahead of the actual
evidence.

What High-Quality Evidence Says About Ivermectin and Hydroxychloroquine

When you strip away the hype and look at well-designed randomized controlled trials and
systematic reviews, a clear pattern appears.

Ivermectin and COVID-19

• Large randomized trials and meta-analyses that focus on reliable studies have generally found
  no clinically meaningful benefit of ivermectin for preventing or treating COVID-19.
• Major organizations including the World Health Organization (WHO), the U.S. National
  Institutes of Health (NIH), and the FDA have concluded that there is insufficient evidence
  to recommend ivermectin for COVID-19, and in many cases explicitly recommend against its use
  outside of clinical trials.
• The FDA has repeatedly stated that ivermectin is not authorized or approved for the
  prevention or treatment of COVID-19, and has warned against using veterinary formulations meant
  for animals, which can lead to serious poisoning.

Hydroxychloroquine and COVID-19

• Multiple large randomized trials have shown that hydroxychloroquine does not improve outcomes
  in hospitalized COVID-19 patients and does not prevent infection when used as prophylaxis.
• After reviewing emerging data, the FDA revoked its Emergency Use Authorization for
  hydroxychloroquine in June 2020, concluding it was unlikely to be effective for COVID-19 and
  raised safety concerns in this context.

From a science-based medicine perspective, both drugs land in a similar place for COVID:
interesting early hypotheses that did not pan out when tested rigorously.

Why People Still Believe Ivermectin (and Hydroxychloroquine) Work

If the best evidence doesn’t support ivermectin or hydroxychloroquine for COVID-19, why do so
many people remain convinced they do? Several forces have been at work:

1. Desperation and timing

These drugs rose to fame when fear was high and good options were scarce. Human brains are
wired to cling to hopeful stories during uncertain times. Once people feel a medication “saved”
them or a family member, later data to the contrary can feel like an insult, not an update.

2. Social media echo chambers

Online communities formed around the idea that “the truth is being suppressed.” Stories of
miraculous recoveries with ivermectin or hydroxychloroquine spread faster than careful trial
results. Algorithms rewarded engagement, not accuracy, creating feedback loops where the most
dramatic claims won.

3. Mistrust of institutions

Surveys in the U.S. have found that people who endorse COVID-19 vaccine misinformation and have
low trust in scientists, physicians, and public health agencies are more likely to report using
ivermectin or hydroxychloroquine for COVID-19. In that dynamic, any caution from mainstream
institutions is reframed as proof of a cover-up rather than a normal part of evidence-based
decision-making.

4. Political identity

In some regions, using these drugs became a political or cultural statement as much as a health
decision. Ivermectin and hydroxychloroquine were promoted by certain commentators as symbols of
“medical freedom” or resistance to elites, which made it even harder for new evidence to change
minds. When a medication is wrapped in identity and ideology, data alone struggles to compete.

The Harms Are Real: “Harmless Experiment” Is a Myth

A common argument is that trying drugs like ivermectin or hydroxychloroquine for COVID-19 is
harmless: “If it doesn’t help, what’s the harm?” Unfortunately, real-world experience shows
several serious downsides.

Medical risks

Both drugs have side effects. Hydroxychloroquine can affect heart rhythm and may be dangerous
for people with certain cardiac conditions or when combined with other medications that prolong
the QT interval. Ivermectin can cause neurologic side effects and toxicity at high doses; using
concentrated veterinary products has led to poisonings and hospitalizations.

Delaying effective care

Time matters with COVID-19. Relying on unproven drugs instead of timely, evidence-based care
such as authorized antivirals, appropriate monitoring, and supportive treatment can mean
people show up to the hospital sicker and harder to treat.

Straining the system

Surges in demand for these medications for off-label COVID use have disrupted access for
patients who need them for approved conditions. Pharmacies have reported spikes in prescriptions
far beyond pre-pandemic levels, mostly driven by COVID-related off-label use. That’s not just a
curiosity; it’s a supply and equity issue.

Eroding trust

When people are told a drug is a “miracle cure” and later discover it doesn’t work, trust in
science and medicine can crumble. That makes it harder to communicate about treatments and
vaccines that actually do have strong evidence behind them.

Science-Based Medicine vs. “Do Your Own Research”

It’s easy to say “just follow the science,” but real science is messy. Early results are
uncertain. Studies can disagree. Retractions happen. Bad actors occasionally manipulate data.
All of this happened in the ivermectin and hydroxychloroquine saga and bad-faith commentators
were quick to weaponize the confusion.

How evidence is supposed to work

Science-based medicine doesn’t hinge on a single study or a dramatic anecdote. It relies on:

• Well-designed randomized controlled trials with enough participants.
• Systematic reviews and meta-analyses that focus on high-quality data.
• Independent replication by different teams in different settings.
• Transparent discussion of limitations, conflicts of interest, and uncertainties.

When that process is allowed to play out for ivermectin and hydroxychloroquine in COVID-19, the
conclusion is consistent: neither drug offers reliable, clinically meaningful benefit for
preventing or treating the disease.

Where “do your own research” goes wrong

On social media, “do your own research” often means reading a handful of cherry-picked,
out-of-context papers or watching long videos by people who sound confident but don’t follow
scientific norms. Individual readers usually don’t have the time or training to evaluate study
design, statistical power, or red flags for data manipulation.

That doesn’t mean you shouldn’t ask questions you absolutely should. But there’s a difference
between healthy skepticism and assuming that decades of infectious-disease expertise can be
replaced with a couple of late-night search sessions.

Lessons Learned: How to Spot the Next “New Hydroxychloroquine”

The ivermectin–hydroxychloroquine saga won’t be the last time a drug is hyped as a miracle
cure. Here are some practical red flags and questions to carry into the future:

• “Miracle cure” language: Science rarely deals in miracles. If a drug is
  described as a suppressed wonder treatment that “they don’t want you to know about,” your
  skepticism should go up.
• One small study vs. many large ones: Are claims based on a tiny early trial
  or a preprint or on multiple large, peer-reviewed randomized trials? Big decisions should
  lean on the latter.
• Who is promoting it? Are claims coming from front-line researchers and major
  clinical societies, or from influencers, talk-show hosts, and loosely organized advocacy
  groups with an agenda?
• Do major health agencies agree? Organizations like the FDA, CDC, NIH, and
  WHO aren’t perfect, but when they converge on a conclusion after reviewing all the data,
  it’s worth listening.
• Is it being used instead of proven care? Even a low-risk experimental drug
  becomes a serious problem if it displaces treatments that actually work.

The goal isn’t blind trust; it’s calibrated trust knowing when a claim is exciting but
tentative, and when it’s been tested enough to be part of standard care.

Experiences from the Ivermectin and Hydroxychloroquine Era

Beyond trial data and regulatory announcements, real people lived through the ivermectin and
hydroxychloroquine waves in ways that were often stressful, confusing, and emotionally charged.
While specific experiences vary, common themes emerged in clinics, pharmacies, and families
across the United States.

In the exam room

Many clinicians describe a kind of “consult whiplash” during the height of these debates. On a
Monday, they might have a patient in tears because their hospitalized parent couldn’t find a
bed. On Tuesday, another patient arrived with a printed protocol from an online group insisting
that ivermectin or hydroxychloroquine was their only hope and implying that any doctor who
disagreed was part of a conspiracy.

Conversations that used to be straightforward explaining risks, benefits, and uncertainties
suddenly required detours through YouTube videos, talk-show segments, and viral Twitter threads.
Doctors and nurses were pressed to prescribe medications they believed (based on the best
evidence available) would not help and might harm. Some faced complaints or online harassment
for refusing to offer what they saw as non-standard, low-value care.

At the pharmacy counter

Pharmacists, too, found themselves on the front lines. Community pharmacies saw surges in
prescriptions for hydroxychloroquine early in the pandemic and ivermectin later on, sometimes
at doses or combinations that raised safety concerns. In certain areas, prescriptions jumped
several-fold above pre-pandemic baselines.

Many pharmacists reported fielding calls from worried patients with lupus or other autoimmune
diseases who suddenly couldn’t fill their usual hydroxychloroquine prescriptions because
supplies were strained. Others had to explain why they were not comfortable filling large
ivermectin prescriptions clearly intended for COVID-19 treatment despite regulatory guidance
against that use.

Inside families and friend groups

For families, the issue often landed like a political and emotional grenade at the dinner
table. One sibling might argue that “doctors are ignoring this cheap cure,” while another
pointed to major trials showing no benefit. Some families quietly went ahead and bought
veterinary ivermectin from feed stores. Others begged relatives to stop self-medicating and
instead talk to their physicians about authorized treatments and vaccination.

These conflicts weren’t just about pills; they were about trust in institutions, in
expertise, and in each other. In many households, COVID-19 treatment choices became shorthand
for deeper beliefs about science, politics, and autonomy.

What clinicians say they’ve learned

Health-care professionals who lived through this period often highlight several lessons:

• Communication matters as much as data. Simply saying “the evidence doesn’t
  support that” rarely changed minds. Taking time to listen to fears, explain how trials work,
  and acknowledge uncertainty helped more than reciting guidelines.
• Trust has to be built before a crisis. Patients who already had a solid,
  long-term relationship with a clinician were generally more open to hearing that a hyped drug
  wasn’t a good idea than those who felt alienated by the health-care system.
• Being honest about uncertainty builds credibility. Early in a pandemic,
  evidence is thin. Saying “we don’t know yet” is uncomfortable but often more trustworthy than
  over-confident claims especially when early hopes don’t pan out.

For many in medicine, ivermectin and hydroxychloroquine became less about the drugs themselves
and more about how fragile the relationship between science and the public can be and how
much work it will take to strengthen that relationship before the next crisis.

Conclusion: Moving Past Miracle Cures and Back to Medicine That Works

Hydroxychloroquine and ivermectin are not villains. They’re important medications in their
proper roles. The problem arises when real drugs are cast as miracle solutions to complex
problems before the evidence is ready, then defended long after science has moved on.

When science-based medicine evaluates ivermectin and hydroxychloroquine for COVID-19, the
verdict is clear: they do not live up to the promises made on talk shows, message boards, or
glossy “protocol” PDFs. Continuing to treat them as miracle cures doesn’t just fail to help; it
risks harm, delays effective care, and erodes public trust.

The next time a new “wonder drug” storms onto your feed, remember this chapter. Ask how big the
studies are, whether they’ve been replicated, what major clinical guidelines say, and whether
someone might be selling more than just hope. Evidence-based medicine is slower and less flashy
than viral hype, but when your health is on the line, boring, careful science is exactly what
you want.